Ovid Therapeutics stockholders elect directors, approve executive compensation, ratify KPMG

Ovid Therapeutics Inc.

Proposal 1: Barbara Duncan and Robert Michael Poole elected to board; For votes 36.7M and 40.2M respectively.
Proposal 2: Advisory vote on executive compensation approved with 40.5M For, 1.76M Against, 0.01M Abstain.
Proposal 3: Ratification of KPMG as auditor for FY2024 passed with 57.2M For, 1.29M Against, 9,375 Abstain.
Broker non-votes totaled 16.2M shares on Proposals 1 and 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.